
Please try another search
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Lewis Clayton Cantley | 73 | - | Member of Scientific Advisory Board |
Rune Nordlander | 69 | 2010 | Director |
Fredrik Lehmann | 49 | 2019 | Independent Director |
Gunilla Enblad | - | - | Member of Scientific Advisory Board |
Bjorn Sjostrand | 56 | 2021 | Independent Chairman of the Board |
Robert J. Devita | - | - | Member of Scientific Advisory Board |
Svein Mathisen | 69 | 2020 | Independent Director |
Karen From | 55 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review